Syntaxin's Series B Round

Syntaxin raised a round of funding on October 01, 2007.

Syntaxin discovers and develops a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSIs) that treat disease through selective inhibition of cell secretory pathways. It is developing TSI…

Articles about Syntaxin's Series B Round: